Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...

Bristol Myers Squibb BMY announced that the FDA has approved xanomeline and trospium chloride (formerly KarXT), an oral ...

Neurocrine's KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose Rather than try to address those issues in a third trial, the biotech has decided to stop development of the ...

(Reuters) – Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.

Since the pioneering psychophysical studies of olfactory recognition memory in patients with schizophrenia by Campbell and Gregson, [19] a number of investigators have reported that schizophrenia ...

The trial enrolled adults with cognitive impairment associated with schizophrenia. Credit: PeopleImages.com – Yuri A / Shutterstock. Neurocrine Biosciences has reported that its Phase II ERUDITE ...